Picture a pharmacist running a busy counter in Pune. A patient buys a strip of a scheduled formulation — say, a common antihypertensive under DPCO 2013 — and the billing software pulls up a price that is ₹2.30 higher than the ceiling printed on the foil. The pharmacist does not notice. The patient does not ask. The transaction goes through. Now picture this happening thirty times a day across a dozen such SKUs. At ₹2.30 per strip on thirty strips a day, that is ₹69 a day, ₹2,070 a month, ₹24,840 a year — collected from patients who had a legal right to pay less, and sitting in the accounts of a pharmacy that has no legal right to keep it.
The law here is not ambiguous. The Drugs (Prices Control) Order, 2013 — DPCO 2013 — fixes ceiling prices for scheduled formulations, and the National Pharmaceutical Pricing Authority (NPPA) revises those prices every year. No retailer, no matter how far they are from Delhi, is exempt from mrp rules pharmacy law. A retailer charging above MRP — even by a fraction, even on a single strip — is in violation of the Essential Commodities Act, 1955, under which DPCO 2013 is notified.
If your billing system is pulling prices from a database that has not been updated since the last NPPA revision, or if your staff are manually overriding prices at the counter, you are exposed to a complaint from any patient, any drug inspector or any consumer forum. The penalty is recoverable by the government; the reputational damage is not. This post explains exactly where the risk comes from and what a compliant billing workflow looks like.
---
When the Distributor Invoice and the Printed MRP Tell Different Stories
Say a shop in Chennai receives a batch of a scheduled cardiac formulation. The distributor's invoice lists a trade price. The MRP printed on the strip reflects the NPPA-notified ceiling as of the print date. But a revised ceiling notification was issued by NPPA after the batch was manufactured and before the batch arrived at the counter.
Under DPCO 2013, the ceiling price for a scheduled formulation is the one in force at the time of sale, not the one printed on the pack — provided the new ceiling is lower. A pharmacist relying only on the printed MRP may, in good faith, charge a price that is no longer legal.
This is not a theoretical edge case. NPPA revises scheduled formulation prices annually under the Wholesale Price Index (WPI) formula, and mid-year notifications are also issued when a new formulation enters the National List of Essential Medicines (NLEM). Say the gap between the printed MRP and the revised ceiling on a single SKU is ₹5. At fifty strips of that SKU sold per month, that is ₹250 a month overcharged — ₹3,000 a year on one line item. A pharmacy carrying twenty such SKUs could be looking at ₹60,000 a year in charges it cannot legally defend.
The risk is not only financial. A patient complaint to the state drug controller triggers an inspection. An inspection that finds a pattern of overcharging above nppa ceiling price can result in a show-cause notice and prosecution under the Essential Commodities Act.
---
The Non-Scheduled Formulation Trap: MRP Is Still the Ceiling
Pharmacies often focus compliance attention on DPCO-scheduled formulations and treat non-scheduled medicines as free-pricing territory. They are — but only up to the MRP the manufacturer has printed and declared. Charging above MRP on any medicine, scheduled or not, violates the Legal Metrology (Packaged Commodities) Rules, 2011, which prohibit a retailer from selling any pre-packaged commodity above its declared MRP.
Say a counter staff member manually edits a billing line because the system has the wrong MRP loaded — perhaps a batch was entered at an old price and the new batch has a slightly different MRP printed on it. The difference might be ₹3 on a bottle of a non-scheduled antibiotic suspension. Small, but the violation is identical in law to charging above MRP on a DPCO formulation.
The only defence is a billing system whose price data is kept current and that refuses to bill above the MRP recorded for a batch.
---
The Dual-Price Problem: When a New Batch Arrives Before the Old One Sells Out
This is the most common source of inadvertent overcharging in dpco 2013 retailer operations. A pharmacy holds two batches of the same molecule: an older batch with a higher printed MRP and a newer batch with a lower MRP (because the manufacturer revised it at the time of printing). Staff reach for whichever box is at the front of the shelf. The billing system may have only one price loaded. The result: a customer buying from the older, higher-MRP batch is billed correctly; a customer buying from the newer, lower-MRP batch is billed above its legal ceiling.
The reverse scenario is equally problematic: an older batch has a lower MRP than a newer batch. Billing software that pulls the wrong batch's price could result in the pharmacy selling below cost on the newer batch — or charging the newer batch's higher price against the older batch's lower MRP, which is charging above mrp.
The fix requires FEFO-aware batch management at the billing counter: each batch tracked separately with its own MRP, and the billing system selecting and displaying the correct batch price at the moment of sale. Without it, a pharmacist handling two hundred transactions a day cannot manually verify batch-level MRP fidelity on every line.
---
What a Compliant Billing Counter Looks Like
The before state is familiar: a billing counter where prices are loaded once at stock entry, updated manually when staff remember, and where two batches of the same SKU share a single price record. Overcharging happens silently. It shows up, if at all, only when a patient questions a bill or a drug inspector walks in.
The after state is a counter where:
- Each batch has its own MRP recorded at the time of stock entry.
- At billing, the system selects the batch to be picked (FEFO — first expiry, first out) and displays that batch's MRP.
- The billing system refuses to accept a sale price above the batch's recorded MRP.
- When a new batch arrives with a different MRP, the pharmacist enters it separately; the old batch and new batch coexist in the system with their respective prices.
The difference in daily effort is small. The difference in compliance exposure is significant. A pharmacy running this workflow has a defensible record: every transaction tied to a batch, every batch tied to an MRP, every MRP verifiable against the physical stock.
---
How Nesayo Handles Batch-Level MRP at the Counter
Picture the moment a new stock consignment arrives at a pharmacy in Ahmedabad. The pharmacist scans or photographs the distributor invoice. Nesayo's prescription photo scan reads the line items and creates a draft stock entry. The pharmacist reviews it, adds the MRP from each batch's physical strip, and confirms. From that moment, each batch lives in the system with its own MRP.
When a customer arrives and the pharmacist starts billing, say, a strip of a DPCO-scheduled antidiabetic, Nesayo applies FEFO batch selection — it surfaces the batch expiring soonest and displays that batch's recorded MRP. The billing system will not accept a sale price above that MRP. If the pharmacist tries to override it upward, the system stops the transaction. Nothing changes unless the pharmacist resolves the discrepancy.
Now picture the same pharmacy two weeks later. A new batch of the same molecule has arrived with a revised, lower MRP — the manufacturer updated it between print runs. The older batch still has the higher MRP on its foil. Nesayo holds both batches separately. When the older batch's stock is exhausted and billing moves to the newer batch, the lower MRP automatically applies. No manual intervention. No risk of billing the newer batch at the older batch's higher price.
Stock Sense, one of Nesayo's five AI agents (available on the AI Employee plan at ₹999 per month as of September 2026), monitors price anomalies across batches of the same SKU and flags cases where two open batches have materially different MRPs — so the pharmacist knows to double-check the physical foil before the discrepancy reaches the counter. The agent asks before it acts; the pharmacist approves any change.
Billing on Nesayo is free. The AI Employee plan, which includes all five agents, is ₹999 per month as of September 2026.
---
The Choice in Front of You Right Now
A pharmacy running on a billing system without batch-level MRP enforcement is not making a conscious choice to overcharge — it is running a process that makes overcharging structurally likely. Every day that passes is another set of transactions that may not withstand scrutiny from a drug inspector or a consumer court. The legal ceiling on scheduled formulations under DPCO 2013 is not negotiable; the NPPA does not issue warnings before it acts on complaints; and a pattern of overcharging, once documented, is difficult to explain away.
The alternative is a billing counter where the system enforces MRP compliance at the transaction level — not as an audit exercise at month-end, but at the moment a price appears on the screen.
Import your stock from a CSV, Excel file or a photo of a distributor invoice at nesayo.com/setup, enter each batch's MRP at stock entry, and every transaction from that point forward is bounded by the price the law allows.
---
FAQ
What is DPCO 2013 and which medicines does it cover?
DPCO 2013 — the Drugs (Prices Control) Order, 2013 — is issued under the Essential Commodities Act, 1955, and gives the NPPA authority to fix ceiling prices for scheduled formulations. A scheduled formulation is a drug whose formulation appears in the National List of Essential Medicines (NLEM). Manufacturers of scheduled formulations may not sell above the NPPA-notified ceiling price; retailers may not charge patients above the MRP printed on the pack or the current ceiling, whichever is lower.
How often does NPPA revise scheduled formulation ceiling prices?
NPPA revises scheduled formulation ceiling prices annually, typically in the first quarter of the calendar year, using a formula tied to the Wholesale Price Index (WPI). Mid-year revisions are also issued when new formulations are added to the NLEM or when the government exercises emergency price-control powers. A pharmacy's billing database needs to reflect the most recently notified ceiling for each scheduled SKU; relying only on the printed MRP is not sufficient if a newer notification has reduced the ceiling.
Can a retailer charge above MRP on non-scheduled medicines in India?
No. The Legal Metrology (Packaged Commodities) Rules, 2011, prohibit any retailer from selling a pre-packaged commodity — including medicines not covered by DPCO 2013 — above its declared MRP. The MRP printed on the pack is the maximum a retailer may charge, inclusive of all taxes. Charging above it is an offence regardless of whether the medicine is a scheduled formulation under DPCO.
What is the penalty for selling above MRP in India?
For DPCO-scheduled formulations, overcharging is recoverable by the NPPA under the Essential Commodities Act. State drug controllers and the NPPA can issue demand notices requiring the retailer to deposit the overcharged amount. For non-scheduled medicines, violations of the Legal Metrology Rules are prosecuted under the Legal Metrology Act, 2009; penalties vary by offence and are determined by the appropriate authority. Consult a legal adviser familiar with pharmaceutical law in your state for advice specific to your situation.
Is FEFO (first expiry, first out) a legal requirement for pharmacies in India?
No specific statutory provision in Indian pharmacy law mandates FEFO by name for retail pharmacies. However, selling an expired medicine is a violation of the Drugs and Cosmetics Act, 1940, and good pharmacy practice guidelines recommend FEFO to prevent accidental dispensing of near-expiry or expired stock. From a compliance standpoint, FEFO is also the safest way to ensure that batch-level MRP data applied at billing matches the physical batch being sold.
If a patient is overcharged above MRP, what can they do?
A patient may file a complaint with the state drug controller, the NPPA's price monitoring cell, or a consumer dispute redressal commission under the Consumer Protection Act, 2019. The NPPA maintains an online complaint portal for overcharging on essential medicines. Complaints are taken seriously; pharmacies found to have a systemic pattern of overcharging may face show-cause notices, recovery demands and inspection.
How do I know if a medicine in my stock is under DPCO 2013 price control?
The NPPA publishes a list of scheduled formulations on its website (nppa.gov.in), along with the current ceiling prices. You can cross-reference the generic name and formulation strength of any SKU against this list. If the molecule and strength match an NLEM entry, the formulation is likely scheduled and subject to ceiling price control. When in doubt, check the manufacturer's latest printed MRP against the NPPA's current notified price for that formulation.
How does Nesayo handle ceiling price compliance at billing?
Nesayo records each batch with its own MRP at stock entry. At billing, the system applies FEFO batch selection and displays the recorded MRP for the selected batch; it will not accept a sale price above that MRP. If two batches of the same SKU have different MRPs — which happens when a manufacturer revises pricing between print runs — each batch retains its own price record and the correct MRP applies automatically as the pharmacy works through its stock. Keeping the MRP data accurate at stock entry is the pharmacist's responsibility; Nesayo enforces the ceiling against whatever MRP is recorded.